Anumana Picks Boston Scientific Exec Maulik Nanavaty to Lead Company

AI-driven heath technology company and portfolio company of nference, Anumana announced the appointment of Maulik Nanavaty as chief executive officer, member of the Board of Directors, and president of nference Ventures. Previous CEO and co-founder of Anumana, Murali Aravamudan is now executive chairman to the Anumana Board of Directors and remains CEO of nference.
 
After 18 years at Boston Scientific, Nanavaty joins Anumana to lead the company as it begins deploying and commercializing its multi-indication ECG-AI platform technology.
 
Nanavaty served as a senior executive, senior VP, and president ay Boston Scientific with extensive knowledge of commercial and operational medical device expertise in the US and international markets. With the Neuromodulation division at Boston Scientific, Nanavaty led the development and commercialization of microelectronic implantable technologies and software which treats neurological diseases and other chronic conditions. He also served as president of Boston Scientific Japan, as well as VP and general manager of International Cardiology with Boston Scientific Japan.
 
“It is a delight to announce and welcome Maulik as the new CEO of Anumana on the heels of the most recent FDA clearance of our breakthrough ECG-AI LEF device. Maulik’s decades of experience developing and bringing to market innovative medical products globally is exactly what is needed to build Anumana into a best-in-class multimodal cardiovascular AI enterprise,” said Aravamudan. “I am confident his leadership will play a pivotal role in guiding Anumana through its next phase of growth.”
 
The company’s ECG-AI platform identifies hidden cardiovascular diseases from standard ECG point of care that lifesaving treatments may be available. The ECG-AI LEF recently received FDA clearance for detecting low injection fraction. Anumana has three additional algorithms in the pipeline for FDA clearance and can multiple partnerships with pharmaceutical companies to further develop and commercialize them. 
 
“Anumana’s mission to unlock the electrical language of the heart in order to improve patient care is incredibly inspiring, and I am grateful for the opportunity to lead its continued progress,” commented Nanavaty. “The company has accomplished fast-paced disruptive innovation within just two years since its founding, in close partnership with Mayo Clinic’s world-renowned cardiologists and business collaborators. Together, we will build on and accelerate this evidence-based innovative platform, bringing our unique AI-based portfolio of cardiac disease related products to market globally, with real world evidence in transforming patient outcomes.”